---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-24-000032"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:02:53.462526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Curis Q1 net loss $11.9M ($2.05/sh); cash $40.7M; topline AML data May 14

## Summary
- Net loss $11.9M vs $11.6M Q1 2023; revenue $2.1M (Erivedge royalties) vs $2.3M.
- Cash, equivalents and investments $40.7M as of March 31, 2024; expected to fund operations into 2025.
- Topline clinical data from TakeAim Leukemia study (emavusertib monotherapy in R/R AML) to be released May 14, 2024.
- Abstracts accepted for ASCO (May 31-Jun 4) and EHA (Jun 13-16); posters on FLT3m and mSF cohorts.
- Updated data for R/R PCNSL and frontline AML triplet combo expected late 2024.

## SEC filing metadata
- accession: 0001108205-24-000032
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/0001108205-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/cris-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-24-000032
- JSON: https://secwatch.observer/filing/0001108205-24-000032.json
- Plain text: https://secwatch.observer/filing/0001108205-24-000032.txt

## Key facts
- Earnings Releases
  CURIS INC reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income net loss of $11.9 million or $2.05 per share on both a basic and diluted basis.
  - Period: first quarter ended March 31, 2024
  - Revenue: $2.1 million
  - Net income: net loss of $11.9 million or $2.05 per share on both a basic and diluted basis
  - Result: reported results
  source text: For the first quarter of 2024, Curis reported a net loss of $11.9 million or $2.05 per share on both a basic and diluted basis as compared to $11.6 million or $2.39 per share on both a basic and diluted basis, for the same period in 2023. Revenues for the first quarter of 2024 were $2.1 million as compared to $2.3 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/0001108205-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.